FDA Clearance Achieved: Atraverse Medical's Hotwire System Revolutionizes Transseptal Access for Safer Left Heart Interventions

System Composition

The Hotwire Transseptal Access System is a "powerful combination," consisting of two key components: the Hotwire RF Generator and the Hotwire RF Guidewire. Don't let their small size fool you, as their capabilities are quite impressive! The Hotwire RF Guidewire has already "demonstrated its prowess" in nearly 2,000 cardiac surgeries, gaining extensive experience. It acts like a precise "navigator," playing a crucial role in ensuring the smooth progress of cardiac surgeries. Meanwhile, the Hotwire RF Generator is no less impressive, playing a vital role in the entire system.

Unique Technical Advantages

Hotwire RF Generator Adopts Advanced Impedance Guidance Technology, Its "Secret Weapon". It's Like Adding a "Safety Shield" to the Surgery, Effectively Reducing RF Exposure in the Left Atrium, Minimizing Surgical Risks and Ensuring Patient Safety. With It, Doctors Have a "Magic Needle" During Surgery, Making Operations More Effective.

Hotwire RF Guidewire is equally remarkable. Specifically designed for electrophysiologists, it provides highly precise left heart access, ensuring more accurate surgical procedures. Moreover, it features "universal sheath compatibility," allowing users to freely choose their preferred techniques during RF ablation, greatly enhancing the flexibility and efficiency of the surgery. It truly serves as a "thoughtful assistant" for doctors.

Clinical Expert Evaluation

Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernard Cardiovascular Center, spoke highly of the Hotwire system after using it. He stated, "In cardiac electrophysiology and structural heart interventions, safely and accurately accessing the left atrium remains one of the most critical steps. Based on my personal clinical experience, the level of control, precision, and ease of operation provided by the Hotwire system has genuinely enhanced the workflow of transseptal procedures." Dr. Devi Nair’s comments are undoubtedly a strong endorsement of the Hotwire system, filling us with confidence in its clinical application prospects.

The Road to Financing

In 2024, the company successfully secured $12.5 million in seed funding, injecting strong momentum into its early development, supporting the smooth completion of FDA clinical trials and early production, and taking a solid first step.

In June 2025, a $29.4 million Series A financing round was completed. This round was led by Mohan Growth Partners, with participation from numerous angel investors, family offices, and medical technology entrepreneurs. This financing brings the company's total funding to over $40 million since its inception, reflecting strong recognition from the capital markets of its potential. The proceeds from this round will be used in several key areas: expanding the manufacturing capacity of the Hotwire left-heart guiding system to prepare for large-scale production; advancing regulatory approval for the accompanying radiofrequency generator to ensure product safety and efficacy; building a commercialization team to accelerate market promotion; and investing in the research and development of next-generation products to maintain technological leadership.

Background of the Entrepreneurial Team

Atraverse Medical was co-founded in 2022 by Dr. Steven Mickelsen, John Slump (current CEO), and Eric Sauter (Chief Operating Officer). These founders are all "big names" in the industry, having previously led the creation of Farapulse, Inc., which they successfully sold to Boston Scientific for an upfront payment of $295 million.

During the development of Farapulse, the team demonstrated exceptional innovation capabilities and business acumen. Their technology gained widespread market recognition and eventually became one of Boston Scientific's hallmark products, receiving FDA approval in January 2024. This successful entrepreneurial journey allowed the team to accumulate extensive experience in electrophysiological procedural innovation and commercialization pathways. These invaluable experiences, akin to "family heirlooms," have laid a solid foundation for the development of Atraverse Medical and instilled great confidence in the future of Atraverse Medical.

This Issue's Planning: Shen Li

Editor-in-Chief: Chen Baolin

Author of This Article: Yun Ye Xuan

Post-production: Zhang Lirong